Cover Image
市場調查報告書

照護現場 (POC) 診斷的全球市場預測 2021年:葡萄糖監測、心血管代謝監測、傳染病檢查套件、心臟標記、腫瘤標記(癌症篩檢)

Point-of-Care Diagnostics Market by Products (Glucose, Cardiometabolic Monitoring, & Infectious Disease Testing Kits, Cardiac & Tumor Markers), End Users (Home, Hospitals, Ambulatory Care), Over-the-Counter & Prescription Based - Global Forecast to 2021

出版商 MarketsandMarkets 商品編碼 298728
出版日期 內容資訊 英文 222 Pages
訂單完成後即時交付
價格
Back to Top
照護現場 (POC) 診斷的全球市場預測 2021年:葡萄糖監測、心血管代謝監測、傳染病檢查套件、心臟標記、腫瘤標記(癌症篩檢) Point-of-Care Diagnostics Market by Products (Glucose, Cardiometabolic Monitoring, & Infectious Disease Testing Kits, Cardiac & Tumor Markers), End Users (Home, Hospitals, Ambulatory Care), Over-the-Counter & Prescription Based - Global Forecast to 2021
出版日期: 2016年07月07日 內容資訊: 英文 222 Pages
簡介

照護現場 (POC) 診斷的市場規模,預計從2016年到2021年以9.8%的年複合成長率發展,到2021年達到369億6,000萬美元。整體POC診斷市場成長,由於全世界的文明病、感染疾病的擴大及居家醫療的趨勢高漲等要素而受促進。

本報告提供全球照護現場 (POC) 診斷/檢驗市場相關調查,市場概要,最近的主要趨勢,各產品區分、終端用戶、處方區分、地區/主要國家的市場規模的變化與預測,市場影響因素,課題等分析,及主要企業簡介等,詳細內容彙整。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 照護現場診斷市場概要
  • 地區分析:POC診斷市場成長率,各產品
  • 地區分析:各POC診斷市場規模,處方法
  • POC診斷市場:各終端用戶、地區

第5章 照護現場 (POC) 診斷的全球市場:概要

  • 簡介
  • 市場區隔
  • 市場動態
    • 推動市場成長要素
    • 阻礙市場成長要素
    • 市場機會
    • 市場課題
    • 緊急的問題

第6章 照護現場 (POC) 診斷產業的趨勢

  • 簡介
  • 產業的趨勢
    • POC檢驗設備的標準化
    • 小規模企業的收購
    • 對微流體為基礎的POC設備的關注度高漲
  • 價格設定與成本的相關分析
  • 波特的五力分析
  • 策略性基準

第7章 照護現場 (POC) 診斷的全球市場:各產品

  • 簡介
  • 葡萄糖監測套件市場
  • 心血管代謝監測套件
    • 心肌標記
    • 血氣/電解質檢測套組
    • HbA1 (格力高血紅素) 檢測套組
    • 脂質檢測套組
  • 傳染病檢查套件
    • 流感檢測套組
    • HIV檢測套組
    • C型肝炎檢測套組
    • 性感染疾病 (STDS) 檢測套組
    • 熱帶病檢測套組
    • 醫療相關感染檢測套組
    • 呼吸系統感染檢測套組的市場
    • 其他傳染病檢查套件
  • 血液凝固監測套件
    • 凝血酵素原時間 (PT/INR) 檢測套組
    • 活性凝固時間 (ACT/APTT) 檢測套組
  • 妊娠及妊娠能力檢測套組
    • 妊娠檢測套組
    • 妊娠能力檢測套組
  • 腫瘤/癌症標記
  • 尿液檢查套件
  • 膽固醇試紙
  • 血液學的檢測套組
  • 藥物濫用檢測套件
  • 航班中潛血檢測套組
  • 其他的檢測套組

第8章 照護現場 (POC) 診斷的全球市場:各處方法

  • 簡介
  • 處方箋需要的檢測套組
  • OTC檢測套組的市場

第9章 照護現場 (POC) 診斷的全球市場:各終端用戶

  • 簡介
  • 專門診斷中心
  • 研究實驗室
  • 居家醫療
  • 其他

第10章 照護現場 (POC) 診斷的全球市場:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 其他的國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 其他的國家
  • 其他 (ROW)

第11章 競爭環境

  • 概要
  • 市場佔有率分析
  • 血中葡萄糖監視套件的市場佔有率分析
  • 競爭情形、趨勢

第12章 企業簡介

  • 簡介
  • ROCHE DIAGNOSTICS LIMITED (F. HOFFMANN-LA ROCHE LTD. 子公司)
  • ABBOTT LABORATORIES, INC.
  • SIEMENS AG
  • ALERE INC.
  • JOHNSON & JOHNSON
  • INSTRUMENTATION LABORATORY (A WERFEN COMPANY)
  • NOVA BIOMEDICAL
  • BECKMAN COULTER, INC. (DANAHER CORPORATION 子公司)
  • BECTON, DICKINSON AND COMPANY
  • PTS DIAGNOSTICS

第13章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MD 2702

The point-of-care diagnostics market is expected to reach USD 36.96 billion by 2021, at a CAGR of 9.8% from 2016 to 2021.

The growth of the overall point-of-care diagnostics market is driven by factors such as prevalence of lifestyle and infectious diseases and the increasing inclination towards home healthcare across the globe. In addition, healthcare decentralization, miniaturization of POC testing devices, increasing number of conferences and events, and POC tests with multiplexing capabilities are offering new growth opportunities for players in the point-of-care diagnostics market. On the other hand, stringent and time-consuming regulatory policies and pricing pressure owing to reimbursement cuts and budget constraints are the key challenges faced by the market players involved in the POC diagnostics market.

In this report, the point-of-care diagnostics market has been segmented on the basis of product (covering glucose monitoring testing kits, cardiometabolic testing kits, infectious disease testing kits, and urinalysis testing kits, among others), mode of prescription (OTC and prescription-based testing kits), end-users (professional diagnostic centers, home care, and research laboratories), and region (North America, Europe, APAC, and RoW). On the basis of products, the glucose monitoring kits segment is estimated to account for the largest share of the point-of-care diagnostics market in 2016. Rising diagnosis of diabetes, ongoing technological advancements in devices used for self-monitoring blood glucose level, and growing patient awareness towards POC testing is driving the growth of this segment across the globe.

Geographically, North America (comprising the U.S. and Canada) is expected to command the largest share of the point-of-care diagnostics market in 2016, followed by Europe. A number of factors such as growing prevalence of lifestyle diseases, increasing number of product approvals, and rising government initiatives are contributing to the growth of the North American point-of-care diagnostics market. However, rising pricing pressure and slow approval of multi-analyte POC products is limiting the growth of point-of-care diagnostics market in North America.

The point-of-care diagnostics market consists of a large number of big, medium, and small-sized companies. As of 2015, the point-of-care diagnostics market was dominated by Roche Diagnostics Limited (Switzerland), Johnson & Johnson (U.S.), and Alere, Inc. (U.S.). New product launches and product approvals; partnerships, agreements, and collaborations; acquisitions; and expansions were the major strategies adopted by most of the market players between 2013 and 2016 to achieve growth in the point-of-care diagnostics market.

Reasons to Buy the Report:

From an insight perspective, this research report focuses on various levels of analysis-market share analysis of top players and company profiles, which together comprise and discuss basic views on the competitive landscape; emerging and high-growth segments of the global point-of-care diagnostics market; and high-growth regions and their respective drivers, restraints, challenges, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms in garnering a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned four strategies (market penetration, product development/innovation, market development, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on point-of-care diagnostic devices offered by the top 10 players in the point-of-care diagnostics market. The report analyzes the point-of-care diagnostic devices market by product and region
  • Product Development/Innovation: Detailed insights on current and upcoming technologies, research and development activities, product enhancements, and new product launches in the point-of-care diagnostics market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various point-of-care diagnostics devices across four geographies
  • Competitive Assessment: Assessment of market shares, strategies, and products of leading players in the point-of-care diagnostics market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
  • 1.4. MARKETS COVERED
    • 1.4.1. YEARS CONSIDERED FOR THE STUDY
  • 1.5. CURRENCY
  • 1.6. LIMITATIONS
  • 1.7. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH DATA
    • 2.1.1. SECONDARY DATA
      • 2.1.1.1. Key data from secondary sources
    • 2.1.2. PRIMARY DATA
      • 2.1.2.1. Key data from primary sources
      • 2.1.2.2. Key industry insights
  • 2.2. MARKET SIZE ESTIMATION METHODOLOGY
    • 2.2.1. BOTTOM-UP APPROACH
    • 2.2.2. TOP-DOWN APPROACH
  • 2.3. RESEARCH DESIGN
  • 2.4. MARKET DATA VALIDATION AND TRIANGULATION
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CURRENT SCENARIO
  • 3.3. FUTURE OUTLOOK
  • 3.4. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. POINT-OF-CARE DIAGNOSTICS MARKET OVERVIEW
  • 4.2. GEOGRAPHIC ANALYSIS: POINT-OF-CARE DIAGNOSTICS MARKET GROWTH RATE, BY PRODUCT (2016-2021)
  • 4.3. GEOGRAPHIC ANALYSIS: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY MODE OF PRESCRIPTION, 2016 VS. 2021
  • 4.4. POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER AND REGION, 2016(USD MILLION)

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
  • 5.3. MARKET DYNAMICS
    • 5.3.1. DRIVERS
      • 5.3.1.1. High prevalence of infectious diseases in developing countries
      • 5.3.1.2. Increasing incidence of lifestyle diseases
      • 5.3.1.3. Rising usage of home-based POC devices
      • 5.3.1.4. Growing government support
      • 5.3.1.5. Private investments and venture capital activities
      • 5.3.1.6. Technological advancements and new product launches
      • 5.3.1.7. Growing number of regulatory approvals for novel immunoassay techniques
      • 5.3.1.8. Shortage of skilled laboratory technicians increasing preference of POC testing
      • 5.3.1.9. Rising number of CLIA-waived POC tests
    • 5.3.2. RESTRAINTS
      • 5.3.2.1. Product recalls
      • 5.3.2.2. Pricing pressures owing to reimbursement cuts and budget constraints hampering profits
      • 5.3.2.3. Stringent and time-consuming regulatory policies are significantly increasing gestation period for product launches
    • 5.3.3. OPPORTUNITIES
      • 5.3.3.1. Emerging markets (India, China, and Brazil) to pave new growth avenues
      • 5.3.3.2. Healthcare decentralization-converting lab tests to POC tests
      • 5.3.3.3. Increasing number of conferences and events
      • 5.3.3.4. Miniaturization of POC testing devices
      • 5.3.3.5. POC tests with multiplexing capabilities
    • 5.3.4. CHALLENGES
      • 5.3.4.1. Lack of alignment with definitive central lab methods
      • 5.3.4.2. Disadvantages of POC testing over central lab methods
      • 5.3.4.3. Inadequate knowledge about use of POC devices in professional settings
      • 5.3.4.4. Reluctance towards changing existing treatment practices
    • 5.3.5. BURNING ISSUES
      • 5.3.5.1. Unfavorable reimbursement limiting the adoption of POC tests
      • 5.3.5.2. High cost of devices-a prime concern
      • 5.3.5.3. Negative public perception related to POC tests

6. INDUSTRY TRENDS

  • 6.1. INTRODUCTION
  • 6.2. INDUSTRY TRENDS
    • 6.2.1. STANDARDIZATION OF POC TESTING DEVICES
    • 6.2.2. ACQUISITION OF SMALL PLAYERS
    • 6.2.3. GROWING FOCUS ON MICROFLUIDICS-BASED POC DEVICES
      • 6.2.3.1. Microfluidics-based LOC devices will bring laboratory testing to the patient's fingertips
      • 6.2.3.2. Evolution of paper-based microfluidic POC diagnostic devices
  • 6.3. PRICING AND COST ANALYSIS
  • 6.4. PORTER'S FIVE FORCES ANALYSIS
    • 6.4.1. THREAT FROM NEW ENTRANTS
    • 6.4.2. THREAT OF SUBSTITUTES
    • 6.4.3. BARGAINING POWER OF SUPPLIERS
    • 6.4.4. BARGAINING POWER OF BUYERS
    • 6.4.5. INTENSITY OF COMPETITIVE RIVALRY
  • 6.5. STRATEGIC BENCHMARKING
    • 6.5.1. TECHNOLOGY INTEGRATION & NEW PRODUCT LAUNCHES
    • 6.5.2. INCORPORATION OF WIRELESS TECHNOLOGY IN POC DEVICES

7. POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT

  • 7.1. INTRODUCTION
  • 7.2. GLUCOSE MONITORING KITS
  • 7.3. CARDIOMETABOLIC MONITORING KITS
    • 7.3.1. CARDIAC MARKERS
    • 7.3.2. BLOOD GAS/ELECTROLYTES TESTING KITS
    • 7.3.3. HBA1C TESTING KITS
    • 7.3.4. LIPID TESTING KITS
  • 7.4. INFECTIOUS DISEASE TESTING KITS
    • 7.4.1. INFLUENZA TESTING KITS
    • 7.4.2. HIV TESTING KITS
    • 7.4.3. HEPATITIS C TESTING KITS
    • 7.4.4. SEXUALLY TRANSMITTED DISEASES (STDS) TESTING KITS
    • 7.4.5. TROPICAL DISEASES TESTING KITS
    • 7.4.6. HEALTHCARE-ASSOCIATED INFECTION TESTING KITS
    • 7.4.7. RESPIRATORY INFECTIONS TESTING KITS
    • 7.4.8. OTHER INFECTIOUS DISEASE TESTING KITS
  • 7.5. COAGULATION MONITORING KITS
    • 7.5.1. PT/INR TESTING KITS
    • 7.5.2. ACTIVATED CLOTTING TIME (ACT/APTT) TESTING KITS
  • 7.6. PREGNANCY AND FERTILITY TESTING KITS
    • 7.6.1. PREGNANCY TESTING KITS
    • 7.6.2. FERTILITY TESTING KITS
  • 7.7. TUMOR/CANCER MARKERS
  • 7.8. URINALYSIS TESTING KITS
  • 7.9. CHOLESTEROL TEST STRIPS
  • 7.10. HEMATOLOGY TESTING KITS
  • 7.11. DRUGS-OF-ABUSE TESTING KITS
  • 7.12. FECAL OCCULT TESTING KITS
  • 7.13. OTHER POC TESTING KITS

8. POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE

  • 8.1. INTRODUCTION
  • 8.2. PRESCRIPTION-BASED TESTING KITS
  • 8.3. OTC TESTING KITS MARKET

9. POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER

  • 9.1. INTRODUCTION
  • 9.2. PROFESSIONAL DIAGNOSTIC CENTERS
    • 9.2.1. HOSPITALS/CRITICAL CARE SETTINGS
    • 9.2.2. OUTPATIENT HEALTHCARE SETTINGS
    • 9.2.3. AMBULATORY CARE SETTINGS
  • 9.3. RESEARCH LABORATORIES
  • 9.4. HOME CARE
  • 9.5. OTHERS

10. POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. U.S.
      • 10.2.1.1. Growing prevalence of lifestyle diseases and rising geriatric population
      • 10.2.1.2. Increasing government and venture capital funding
      • 10.2.1.3. Growing number of product approvals using CLIA waiver
      • 10.2.1.4. NIH support for the development of POC testing devices
      • 10.2.1.5. Slow inflow of multi-analyte POC devices
    • 10.2.2. CANADA
      • 10.2.2.1. Expanding patient population base
      • 10.2.2.2. Increasing focus of players on the Canadian market
      • 10.2.2.3. Increasing government initiatives
      • 10.2.2.4. Lack of reimbursement and awareness
  • 10.3. EUROPE
    • 10.3.1. GERMANY
      • 10.3.1.1. Increasing number of conferences
      • 10.3.1.2. Ongoing development of novel products
      • 10.3.1.3. Rising incidence of diabetes and cancer in Germany
      • 10.3.1.4. Low reimbursement affecting market growth in the country
    • 10.3.2. FRANCE
      • 10.3.2.1. Increasing reimbursement for point-of-care tests
      • 10.3.2.2. High prevalence of diabetes in France
    • 10.3.3. U.K.
      • 10.3.3.1. Growing number of new product launches
      • 10.3.3.2. Increasing government support for POCT devices
      • 10.3.3.3. Budget constraints hampering market growth
    • 10.3.4. REST OF EUROPE (ROE)
  • 10.4. ASIA-PACIFIC
    • 10.4.1. JAPAN
      • 10.4.1.1. Growing initiatives by market players
      • 10.4.1.2. Increasing demand for rapid flu tests in Japan
      • 10.4.1.3. Centralized healthcare delivery system
    • 10.4.2. CHINA
      • 10.4.2.1. Increasing partnerships and joint ventures fueling market growth
      • 10.4.2.2. Increasing support from government and private companies
      • 10.4.2.3. Poor reimbursement and time-consuming product registration procedure
    • 10.4.3. INDIA
      • 10.4.3.1. Increasing prevalence of target diseases
      • 10.4.3.2. Growing government initiatives
      • 10.4.3.3. Conferences
      • 10.4.3.4. Lack of reimbursement and insurance coverage hampering market growth
    • 10.4.4. REST OF ASIA-PACIFIC
  • 10.5. REST OF THE WORLD (ROW)
      • 10.5.1.1. Increasing patient population in Africa
      • 10.5.1.2. Huge patient base for respiratory diseases
      • 10.5.1.3. Growing initiatives by market players

11. COMPETITIVE LANDSCAPE

  • 11.1. OVERVIEW
  • 11.2. MARKET SHARE ANALYSIS
  • 11.3. COMPETITIVE SITUATION AND TRENDS
    • 11.3.1. NEW PRODUCT LAUNCHES,PRODUCT ENHANCEMENTS, AND PRODUCT APPROVALS
    • 11.3.2. AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
    • 11.3.3. PRODUCT SHOWCASE AND PRODUCT RECALL
    • 11.3.4. ACQUISITIONS
    • 11.3.5. OTHER STRATEGIES

12. COMPANY PROFILES *(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*

  • 12.1. INTRODUCTION
  • 12.2. ROCHE DIAGNOSTICS LIMITED (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD.)
  • 12.3. ABBOTT LABORATORIES, INC.
  • 12.4. SIEMENS AG
  • 12.5. ALERE INC.
  • 12.6. JOHNSON & JOHNSON
  • 12.7. INSTRUMENTATION LABORATORY (A WERFEN COMPANY)
  • 12.8. NOVA BIOMEDICAL
  • 12.9. BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER CORPORATION)
  • 12.10. BECTON, DICKINSON AND COMPANY
  • 12.11. PTS DIAGNOSTICS

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. DISCUSSION GUIDE
  • 13.2. OTHER DEVELOPMENTS
  • 13.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.5. AVAILABLE CUSTOMIZATIONS
  • 13.6. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 2: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 3: GLUCOSE MONITORING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 4: CARDIOMETABOLIC MONITORING KITS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 5: CARDIOMETABOLIC MONITORING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 6: CARDIAC MARKERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 7: BLOOD GAS/ELECTROLYTES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 8: HBA1C TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 9: LIPID TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 10: INFECTIOUS DISEASE TESTING KITS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 11: INFECTIOUS DISEASE TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 12: INFLUENZA TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 13: HIV TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 14: HEPATITIS C TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 15: STD TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 16: TROPICAL DISEASES TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 17: HEALTHCARE-ASSOCIATED INFECTION TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 18: RESPIRATORY INFECTIONS TESTING KITS MARKET SIZE, BY REGION, 2014--2021 (USD MILLION)
  • TABLE 19: OTHER INFECTIOUS DISEASE TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 20: COAGULATION MONITORING KITS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 21: COAGULATION MONITORING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 22: PT/INR TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 23: ACT/APTT TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 24: PREGNANCY AND FERTILITY TESTING KITS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 25: PREGNANCY AND FERTILITY TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 26: PREGNANCY TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 27: FERTILITY TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 28: TUMOR/CANCER MARKERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 29: URINALYSIS TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 30: CHOLESTEROL TEST STRIPS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 31: HEMATOLOGY TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 32: DRUGS-OF-ABUSE TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 33: FECAL OCCULT TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 34: OTHER POC TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 35: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 36: PRESCRIPTION-BASED TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 37: OTC TESTING KITS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 38: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 39: PROFESSIONAL DIAGNOSTIC CENTERS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 40: PROFESSIONAL DIAGNOSTIC CENTERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 41: RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 42: HOME CARE MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 43: OTHER END USERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 44: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 45: NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 46: NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 47: NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 48: NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 49: U.S.: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 50: U.S.: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 51: U.S.: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 52: CANADA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 53: CANADA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 54: CANADA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 55: EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 56: EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 57: EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 58: EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 59: GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 60: GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 61: GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 62: FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 63: FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 64: FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 65: U.K.: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 66: U.K.: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 67: U.K.: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 68: ROE: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 69: ROE: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 70: ROE: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 71: APAC: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 72: APAC: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 73: APAC: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 74: APAC: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 75: JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 76: JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 77: JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 78: CHINA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 79: CHINA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 80: CHINA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 81: INDIA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 82: INDIA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 83: INDIA: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 84: ROAPAC: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 85: ROAPAC: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 86: ROAPAC: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 87: ROW: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 88: ROW: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY PRESCRIPTION MODE, 2014-2021 (USD MILLION)
  • TABLE 89: ROW: POINT-OF-CARE DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 90: TOP 5 NEW PRODUCT LAUNCHES, PRODUCT ENHANCEMENTS, AND PRODUCT APPROVALS, 2015 & 2016
  • TABLE 91: TOP 5 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS, 2015 & 2016
  • TABLE 92: PRODUCT SHOWCASE AND PRODUCT RECALL, 2013 & 2014
  • TABLE 93: ACQUISITIONS, 2013 & 2014
  • TABLE 94: TOP 5 OTHER STRATEGIES, 2013-2015

LIST OF FIGURES

  • FIGURE 1: GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET: RESEARCH METHODOLOGY STEPS
  • FIGURE 2: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: DATA TRIANGULATION METHODOLOGY
  • FIGURE 4: GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2016 (USD MILLION)
  • FIGURE 5: GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2016 VS. 2021
  • FIGURE 6: GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2016 VS. 2021
  • FIGURE 7: GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION, 2016-2021 (USD MILLION)
  • FIGURE 8: INCREASING PREVALENCE OF INFECTIOUS AND LIFESTYLE DISEASES IS DRIVING GROWTH IN THE POINT-OF-CARE DIAGNOSTICS MARKET
  • FIGURE 9: THE INFECTIOUS DISEASE TESTING KITS SEGMENT IN THE ASIA-PACIFIC REGION TO OFFER LUCRATIVE GROWTH OPPORTUNITIES FOR MARKET PLAYERS
  • FIGURE 10: PRESCRIPTION-BASED TESTING KITS SEGMENT TO DOMINATE THE POINT-OF-CARE DIAGNOSTICS MARKET IN 2016
  • FIGURE 11: PROFESSIONAL DIAGNOSTIC CENTERS TO DOMINATE THE GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET IN 2016
  • FIGURE 12: POC DIAGNOSTICS MARKET SEGMENTATION
  • FIGURE 13: POC DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 14: GLOBAL NUMBER HIV PATIENTS, 2014 (MILLION)
  • FIGURE 15: INCIDENCE RATE OF TB IN DEVELOPING NATIONS, 2014
  • FIGURE 16: ESTIMATED NUMBER OF DIABETIC PATIENTS, BY REGION, 2015 VS. 2040
  • FIGURE 17: HEALTHCARE DECENTRALIZATION ACROSS PROMINENT COUNTRIES, 2013
  • FIGURE 18: PRICING TREND (2013-2018): TWOFOLD DECLINE EXPECTED IN THE PRICE OF POC DEVICES IN APAC AS COMPARED TO NORTH AMERICA
  • FIGURE 19: PORTER'S FIVE FORCES ANALYSIS (2016): LOW CAPITAL REQUIREMENT INCREASING COMPETITION IN THE INDUSTRY
  • FIGURE 20: STRATEGIC BENCHMARKING: ROCHE AND ABBOTT LARGELY FOCUS ON TECHNOLOGICAL INTEGRATION AND PRODUCT ENHANCEMENT
  • FIGURE 21: STRATEGIC BENCHMARKING: ALERE AND ABBOTT LARGELY ADOPT STRATEGIES FOR PRODUCT ENHANCEMENT
  • FIGURE 22: THE INFECTIOUS DISEASE TESTING KITS SEGMENT IS PROJECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 23: NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET IN 2016
  • FIGURE 24: NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL GLUCOSE MONITORING KITS MARKET IN 2016
  • FIGURE 25: THE BLOOD GAS/ELECTROLYTES SEGMENT TO WITNESS HIGHEST GROWTH IN THE GLOBAL CARDIOMETABOLIC MONITORING KITS MARKET DURING THE FORECAST PERIOD
  • FIGURE 26: ASIA-PACIFIC TO WITNESS HIGHEST GROWTH IN THE GLOBAL CARDIOMETABOLIC MONITORING KITS MARKET DURING THE FORECAST PERIOD
  • FIGURE 27: NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL BLOOD GAS/ELECTROLYTES MARKET IN 2016
  • FIGURE 28: HEPATITIS C TESTING KITS SEGMENT TO WITNESS HIGHEST GROWTH IN THE GLOBAL INFECTIOUS DISEASE TESTING KITS MARKET DURING THE FORECAST PERIOD
  • FIGURE 29: NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL INFECTIOUS DISEASES TESTING KITS MARKET IN 2016
  • FIGURE 30: ASIA-PACIFIC TO WITNESS HIGHEST GROWTH IN THE GLOBAL HEPATITIS C TESTING KITS MARKET IN 2016
  • FIGURE 31: ASIA-PACIFIC TO WITNESS HIGHEST GROWTH IN THE GLOBAL HAI TESTING KITS MARKET IN 2016
  • FIGURE 32: NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL PREGNANCY & FERTILITY TESTING KITS MARKET IN 2016
  • FIGURE 33: NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL HEMATOLOGY TESTING KITS MARKET IN 2016
  • FIGURE 34: ASIA-PACIFIC TO WITNESS HIGHEST GROWTH IN THE GLOBAL FECAL OCCULT TESTING KITS MARKET DURING THE FORECAST PERIOD
  • FIGURE 35: OTC TESTING KITS SEGMENT TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 36: NORTH AMERICA TO DOMINATE THE PRESCRIPTION-BASED TESTING KITS MARKET IN 2016
  • FIGURE 37: ASIA-PACIFIC TO WITNESS HIGHEST GROWTH IN THE OTC TESTING KITS SEGMENT
  • FIGURE 38: BROAD END-USER BASE FOR POINT-OF-CARE TESTING KITS
  • FIGURE 39: HOME CARE END-USER SEGMENT TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 40: NORTH AMERICA TO DOMINATE THE PROFESSIONAL DIAGNOSTIC CENTERS MARKET IN 2016
  • FIGURE 41: ASIA-PACIFIC TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 42: POINT-OF-CARE DIAGNOSTICS MARKET: GROWTH FORECAST, BY REGION (2016-2021)
  • FIGURE 43: NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 44: EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 45: APAC: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 46: GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015
  • FIGURE 47: BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES, PRODUCT ENHANCEMENTS, AND PRODUCT APPROVALS-KEY GROWTH STRATEGY ADOPTED BETWEEN 2013 & 2016
  • FIGURE 48: GEOGRAPHIC REVENUE SNAPSHOT (2015)
  • FIGURE 49: ROCHE DIAGNOSTICS LIMITED: COMPANY SNAPSHOT
  • FIGURE 50: ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT
  • FIGURE 51: SIEMENS AG: COMPANY SNAPSHOT
  • FIGURE 52: ALERE INC.: COMPANY SNAPSHOT
  • FIGURE 53: JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • FIGURE 54: DANAHER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 55: BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
Back to Top